Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

8.0K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
8.0K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

713
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
713
Radiological Investigation III: Pulmonary Angiogram and PET Scan01:13

Radiological Investigation III: Pulmonary Angiogram and PET Scan

611
Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
611

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PET-Based Personalized Management in Clinical Oncology: An Unavoidable Path for the Foreseeable Future.

PET clinics·2016
Same author

Evolving Role of Molecular Imaging with (18)F-Sodium Fluoride PET as a Biomarker for Calcium Metabolism.

Current osteoporosis reports·2016
Same author

Ocular Melanoma and Other Unusual Sites.

PET clinics·2016
Same author

Other PET Tracers and Prospects for the Future.

PET clinics·2016
Same author

Normal Variants and Effects of Aging on the Gastrointestinal Tract.

PET clinics·2016
Same author

PET and PET/CT in Pediatric Gastrointestinal Tract Oncology.

PET clinics·2016

Related Experiment Video

Updated: Mar 17, 2026

Enhancing Efficiency and Radiolabeling Yields of Carbon-11 Radioligands for Clinical Research Using the Loop Method
09:08

Enhancing Efficiency and Radiolabeling Yields of Carbon-11 Radioligands for Clinical Research Using the Loop Method

Published on: December 20, 2024

2.0K

Positron emission tomography: ligand imaging.

Mateen Moghbel1, Andrew Newberg2, Abass Alavi3

  • 1Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.

Handbook of Clinical Neurology
|July 20, 2016
PubMed
Summary
This summary is machine-generated.

Positron emission tomography (PET) offers valuable insights into brain function for neurologic and psychiatric conditions. Ongoing development of novel radiopharmaceuticals promises to expand PET

Keywords:
FDGPETPET-CTbrain imagingneuroimagingradiopharmaceuticalsreceptor imaging

More Related Videos

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

2.0K
Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
09:55

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Published on: October 4, 2024

1.0K

Related Experiment Videos

Last Updated: Mar 17, 2026

Enhancing Efficiency and Radiolabeling Yields of Carbon-11 Radioligands for Clinical Research Using the Loop Method
09:08

Enhancing Efficiency and Radiolabeling Yields of Carbon-11 Radioligands for Clinical Research Using the Loop Method

Published on: December 20, 2024

2.0K
Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

2.0K
Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
09:55

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Published on: October 4, 2024

1.0K

Area of Science:

  • Neuroimaging
  • Radiochemistry
  • Nuclear Medicine

Background:

  • Positron emission tomography (PET) has been a key neuroimaging tool since 1976.
  • PET applications span neurologic and psychiatric research, examining cerebral metabolism and receptor concentration.
  • While (18)F-fluorodeoxyglucose is widely used clinically, most PET radiopharmaceuticals remain in research.

Purpose of the Study:

  • To review the current state and future prospects of PET radiopharmaceuticals in neurology and psychiatry.
  • To highlight the challenges and advancements in developing and utilizing PET ligands.
  • To discuss the clinical and research applications of PET imaging.

Main Methods:

  • Review of existing literature on PET imaging and radiopharmaceuticals.
  • Discussion of established and emerging PET ligands, including (18)F-fluorodeoxyglucose.
  • Analysis of challenges such as blood-brain barrier penetration and kinetic modeling.

Main Results:

  • (18)F-fluorodeoxyglucose is a prevalent clinical PET tracer for measuring metabolism.
  • Several novel PET ligands have received FDA approval for clinical use.
  • Significant challenges remain in radiopharmaceutical development and application, including BBB traversal and data analysis.

Conclusions:

  • PET imaging is crucial for understanding brain function in health and disease.
  • Advancements in radiopharmaceutical development are expanding the clinical utility of PET.
  • Overcoming technical hurdles will further enhance the role of PET in neurology and psychiatry.